Granules India share news, announcements and annual reports
NSE: GRANULESBSE: 532482Pharmaceuticals & BiotechnologySmall Cap
Granules India Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2002 on BSE, Jun 2005 on NSE
Last close ₹840.45up ₹9.90 (1.19%)BSE ₹840.15
Share price at the NSE close on 28 Oct 2026. Previous close ₹830.55.
28 Oct: open ₹824.00, high ₹844.55, low ₹824.00
52-week range of traded prices to 28 Oct 2026
₹529.85Low, 25 Nov 2025₹923.65High, 15 Sep 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹22,926 Cr403rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.21%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,29,75449.0% delivered
Granules India disputes and clarifications
15 filed, newest first.
May 2026
28 May · Legal
The exchange asked on 27 May 2026
Feb 2025
28 Feb · Legal
Aug 2023
Jul 2023
11 Jul · Legal
Exchange has sought clarification from Granules India Limited with respect to announcement dated 29-Jun-2023, regarding 'Update on IT Security Incident'. On basis of above the Company is required to clarify following: 1. The actual amount of damage caused due to the natural calamity or other force majeure events.The response of the Company is awaited.
May 2022
26 May · Legal
Exchange has sought clarification from Granules India Limited for the quarter ended 31-Mar-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Consolidated Financial Results not submitted The response of the Company is awaited.
Dec 2021
14 Dec · Legal
Exchange has sought clarification from Granules India Limited with respect to announcement dated 13-Dec-2021, regarding appointment of Dr. Saumen Chakraborty as an Non-Executive Independent Director of the Company. On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.The response of the Company is awaited.
Dec 2019
27 Dec · Legal
Exchange has sought clarification from Granules India Limited with respect to announcement dated 26-Dec-2019, regarding Resignation of Mr C Parthasarathy as Independent Director of the company w.e.f. December 26, 2019. On basis of above the Company is required to clarify following: 1. Detailed Reasons for Resignation 2. Confirmation from resigning Independent Director that there are no other material reasons other than provided as per clause 7(B) of para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The response of the Company is awaited.
Jan 2017
5 Jan · Legal
Exchange has sought clarification from Granules India Limited with respect to announcement dated 04-Jan-2017, regarding appointment of Dr. V.V.N.K.V. Prasada Raju as an Additional Director and designated as Executive Director on the Board of the Company.On basis of above the Company is required to clarify following:1. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.
Jul 2016
20 Jul · Legal
Exchange has sought clarification from Granules India Limited with respect to an announcement submitted to the Exchange dated July 14, 2016, regarding a press release dated July 14, 2016, titled "Granules Pharmaceuticals, Inc., a wholly owend subsidiary of Granules India Limited, entered in to an agreement with USpharma for acquiring its stake".On basis of above Company are required to clarify following -1. Name of the target entity, details in brief such as size, turnover etc;2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";3. Brief details of any governmental or regulatory approvals required for the acquisition;4. Indicative time period for completion of the acquisition;5. Cost of acquisition or the price at which the shares are acquired;6. Nature of consideration - whether cash consideration or share swap and details of the same;7. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).The response of the Company is awaited.
Apr 2007
5 Apr · Legal
Granules India Limited had informed the Exchange that the Board of Directors of the Company at their meeting held on April 03, 2007 considered and approved issue of 22,11,200 equity shares of Rs.10/- each fully paid-up at Rs.105.50 per share (including premium) to ISP Investco LLC., on preferential basis, subject to the approval of the shareholders of the Company. The Company has now informed the Exchange that: "On issue of 22,11,200 equity shares to ISP Investco LLC at Rs.105.50 per share on preferential basis, which will be around 13% holding in the Company (post-issue). In some of the news papers, it was mentioned as acquisition of 18% stake in the Company. We would like to clarify you that the acquisition of stake will be below 15% only".